reports
Share buy-back program
Share buy-back program COMPANY ANNOUNCEMENT NO 37/2025 - July 14, 2025 On February 25, 2025, Royal Unibrew initiated a share buy-back program, cf. company announcement no. 3/2025 of February 25, 2025. The program is carried out under Art. 5 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of April 16, 2014, on market abuse, as amended (the Market Abuse Regulation - MAR) and the Commission Delegated Regulation (EU) No 2016/1052 of March 8, 2016. The share buy-back program is expected to be realized in the period from February 26, 2025, to August 15, 2025....
Share buy-back program
Share buy-back program COMPANY ANNOUNCEMENT NO 36/2025 - JULY 7, 2025 On February 25, 2025, Royal Unibrew initiated a share buy-back program, cf. company announcement no. 3/2025 of February 25, 2025. The program is carried out under Art. 5 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of April 16, 2014, on market abuse, as amended (the Market Abuse Regulation - MAR) and the Commission Delegated Regulation (EU) No 2016/1052 of March 8, 2016. The share buy-back program is expected to be realized in the period from February 26, 2025, to August 15, 2025. The to...
Share buy-back program
Share buy-back program COMPANY ANNOUNCEMENT NO 35/2025 - June 30, 2025 On February 25, 2025, Royal Unibrew initiated a share buy-back program, cf. company announcement no. 3/2025 of February 25, 2025. The program is carried out under Art. 5 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of April 16, 2014, on market abuse, as amended (the Market Abuse Regulation - MAR) and the Commission Delegated Regulation (EU) No 2016/1052 of March 8, 2016. The share buy-back program is expected to be realized in the period from February 26, 2025, to August 15, 2025. The...
Share buy-back program
Share buy-back program COMPANY ANNOUNCEMENT NO 34/2025 - June 23, 2025 On February 25, 2025, Royal Unibrew initiated a share buy-back program, cf. company announcement no. 3/2025 of February 25, 2025. The program is carried out under Art. 5 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of April 16, 2014, on market abuse, as amended (the Market Abuse Regulation - MAR) and the Commission Delegated Regulation (EU) No 2016/1052 of March 8, 2016. The share buy-back program is expected to be realized in the period from February 26, 2025, to August 15, 2025. The t...
Share buy-back program
Share buy-back program COMPANY ANNOUNCEMENT NO 33/2025 - June 16, 2025 On February 25, 2025, Royal Unibrew initiated a share buy-back program, cf. company announcement no. 3/2025 of February 25, 2025. The program is carried out under Art. 5 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of April 16, 2014, on market abuse, as amended (the Market Abuse Regulation - MAR) and the Commission Delegated Regulation (EU) No 2016/1052 of March 8, 2016. The share buy-back program is expected to be realized in the period from February 26, 2025, to August 15, 2025. The t...
Major shareholder announcement
Major shareholder announcement COMPANY ANNOUNCEMENT NO 32/2025 - June 10, 2025 According to Section 30 of the Danish Capital Markets Act, Royal Unibrew A/S hereby announces that we have received notification from Wellington Management Group LLP on changes in Wellington Management Group LLP and its subsidiaries’ holding of shares and voting rights in Royal Unibrew A/S which occurred on 6 June 2025, cf. the attached. For further information please contact:Flemming Ole Nielsen (Head of Investor Relations)E-mail: Telephone: Attachments ...
Share buy-back program
Share buy-back program COMPANY ANNOUNCEMENT NO 31/2025 - June 10, 2025 On February 25, 2025, Royal Unibrew initiated a share buy-back program, cf. company announcement no. 3/2025 of February 25, 2025. The program is carried out under Art. 5 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of April 16, 2014, on market abuse, as amended (the Market Abuse Regulation - MAR) and the Commission Delegated Regulation (EU) No 2016/1052 of March 8, 2016. The share buy-back program is expected to be realized in the period from February 26, 2025, to August 15, 2025. The t...
Share buy-back program
Share buy-back program COMPANY ANNOUNCEMENT NO 30/2025 - June 2, 2025 On February 25, 2025, Royal Unibrew initiated a share buy-back program, cf. company announcement no. 3/2025 of February 25, 2025. The program is carried out under Art. 5 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of April 16, 2014, on market abuse, as amended (the Market Abuse Regulation - MAR) and the Commission Delegated Regulation (EU) No 2016/1052 of March 8, 2016. The share buy-back program is expected to be realized in the period from February 26, 2025, to August 15, 2025. The to...
Share buy-back program
Share buy-back program COMPANY ANNOUNCEMENT NO 29/2025 - May 27, 2025 On February 25, 2025, Royal Unibrew initiated a share buy-back program, cf. company announcement no. 3/2025 of February 25, 2025. The program is carried out under Art. 5 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of April 16, 2014, on market abuse, as amended (the Market Abuse Regulation - MAR) and the Commission Delegated Regulation (EU) No 2016/1052 of March 8, 2016. The share buy-back program is expected to be realized in the period from February 26, 2025, to August 15, 2025. The to...
Launch of Long-Term Incentive Plan for executive management and key em...
Launch of Long-Term Incentive Plan for executive management and key employees COMPANY ANNOUNCEMENT NO 28/2025 – MAY 22, 2025 Royal Unibrew A/S launches a new share-based Long-Term Incentive Plan (LTIP) for executive management and selected key employees for 2025. The plan is designed to align the interests of Royal Unibrew’s employees and shareholders and to retain employees. The new LTIP for 2025 has been approved by the Board of Directors. The LTIP is based on Performance Share Units (PSU) granted to each key employee. The PSUs are granted in 2025 for vesting on the date the Board of ...
- ABGSC IT Research
- Herman Caspersen
- Øystein Elton Lodgaard
- ABGSC IT Research
- Herman Caspersen
- Øystein Elton Lodgaard
Share buy-back program
Share buy-back program COMPANY ANNOUNCEMENT NO 27/2025 - May 19, 2025 On February 25, 2025, Royal Unibrew initiated a share buy-back program, cf. company announcement no. 3/2025 of February 25, 2025. The program is carried out under Art. 5 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of April 16, 2014, on market abuse, as amended (the Market Abuse Regulation - MAR) and the Commission Delegated Regulation (EU) No 2016/1052 of March 8, 2016. The share buy-back program is expected to be realized in the period from February 26, 2025, to August 15, 2025. The to...
Ambu AS: 1 director
A director at Ambu AS bought 2,800 shares at 15.412USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showin...
Share buy-back program
Share buy-back program COMPANY ANNOUNCEMENT NO 26/2025 - May 12, 2025 On February 25, 2025, Royal Unibrew initiated a share buy-back program, cf. company announcement no. 3/2025 of February 25, 2025. The program is carried out under Art. 5 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of April 16, 2014, on market abuse, as amended (the Market Abuse Regulation - MAR) and the Commission Delegated Regulation (EU) No 2016/1052 of March 8, 2016. The share buy-back program is expected to be realized in the period from February 26, 2025, to August 15, 2025. The to...
Novo Nordisk AS: 1 director
A director at Novo Nordisk AS sold 40,000 shares at 450.528DKK and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
- Rune Majlund Dahl
Zealand Pharma (Buy, TP: DKK950.00) - Dapiglutide likely next catalyst
Q1 revenue missed expectations on lower reimbursement revenue, while operating profit was a beat, as opex was below our forecast and consensus. The 2025 guidance was maintained for opex of DKK2,000m–2,500m. We believe the next potential share-price catalyst is the top-line results from the phase Ib dapiglutide trial in Q2e. We reiterate our BUY, but have cut our target price to DKK950 (1,000).
- ABGSC Healthcare Research
- Morten Larsen
- Jesper Ingildsen
Ambu (Buy, TP: DKK144.00) - Possibly isolated softness
Q2 was below our forecast, but the softness might be isolated to Q2 on what could be Chinese competitors dumping stock ahead of tariffs, which could become a tailwind. Notably, the 2024/25 guidance was maintained and includes headwinds from FX and tariffs. We reiterate our BUY, but have cut our target price to DKK144 (155).
- Rune Majlund Dahl
Novo Nordisk (Buy, TP: DKK900.00) - Accelerated Wegovy roll-out ahead
Q1 LCY figures beat our forecasts, while the 2025 guidance was cut to 13–21% LCY sales growth YOY and 16–24% LCY operating profit growth YOY due to weaker GLP-1 sales. We have lowered our rebate for US Ozempic but maintain our 52% Wegovy rebate (in line with the Q1 rebate when adjusting for de-stocking). We reiterate our BUY and DKK900 target price.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.